Labiotech.eu

News and Trends 2 Sep 2016

This €18M Joint Venture could Scale Up Bioplastic Film Production

Roughly 300 million tons of plastic are produced globally every year, but only 700 thousand tons are bio-based and biodegradable. Carbios’s new Joint Venture aims to dramatically grow this market. Carbios has announced the formation of CARBIOLICE, a new French joint venture shared between it, Limagrain Céréales Ingrédients (a heavyweight in the field of mulching films) […]

September 2, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 1 Sep 2016

Infographic: How Cancer Starts & How It Chooses Organs

Here’s a neat infographic from Cancer Research UK summarizing a new Cell report from UK researchers that describes how conditions build to trigger cancer. This information would help to explain the greater vulnerability of certain organs to tumors compared to others. The team, headed by Richard James Gilbertson, demonstrated that while cells may start with equal carcinogenic risk, tumor […]

September 1, 2016 - 1 minutemin - By Evelyn Warner

News and Trends 1 Sep 2016

Cevec: “Our Special Cell Lines will help the next generation of Gene Therapy”

Cevec could very well be the missing link between adenoviral vectors and approved gene therapies. I had a chat with the CSO of Cevec about what makes its technology great and how it’s ready for the future of gene therapy. Gene therapy is one of the strongest trends in biotechnology right now. The field has […]

September 1, 2016 - 6 minutesmins - By Denise Neves Gameiro

News and Trends 1 Sep 2016

GSK is Advancing a Revolutionary Dual HIV Therapy

Gilead has long been the leader in HIV treatments, but GlaxoSmithKline’s CEO revealed to the WSJ that the company has been investing in the field. It could give Gilead a run for its money with dolutegravir, a new integrase inhibitor so powerful it may knock the standard down from triple to dual therapy. Since the […]

September 1, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 31 Aug 2016

Novartis’ second FDA Biosimilar Approval could unlock Billions

Novartis just attained FDA approval for a second biosimilar in the US. Erelzi will unlock the €4.5B rheumatoid arthritis market cornered by Enbrel. Sandoz, a division of Novartis based in the Munich area, has taken home another trophy from the biosimilar battleground by scoring a second FDA approval for its copycat, Erelzi (etanercept-szzs). This drug mimics Enbrel, a €4.5B franchise managed by Amgen in the US that treats rheumatoid arthritis as well […]

August 31, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 31 Aug 2016

World’s most advanced Artificial Heart started its last Study before Approval

This artificial heart could replace any defective heart. It’s being developed by the French company Carmat, which just started the last clinical phase before market approval. Carmat is solving one of the life-long problems for humans, how to replace a broken heart. It’s not the first to offer a solution (e.g. Robert Jarvik in the US), […]

August 31, 2016 - 3 minutesmins - By Philip Hemme

News and Trends 31 Aug 2016

Discover the best Refresh Program we’ve ever made!

Hi there, I’m excited to show you what we have been cooking for our next Labiotech Refresh event in Paris on Nov 24th. We’ve been working hard on bringing in top-notch speakers to build up what we think is our most exciting program so far. Some of the highlights include a Keynote of French Biotech […]

August 31, 2016 - 1 minutemin - By Philip Hemme

News and Trends 31 Aug 2016

No Tumour, No Cancer Cure: New Epigenetic Test can pinpoint Elusive Ones

Not all tumours are detectable, which makes them particularly deadly. Researchers at the University of Barcelona have developed an epigenetic test to find them, the first of its kind to diagnose tumour sources. Cancer starts with a tumour, which grows and eventually sheds cells. These cells lodge in other tissues in the body and grow […]

August 31, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 30 Aug 2016

New non-amphetaminic ADHD drug ‘speeds’ into Phase II

ADHD is believed to affect up to 7% of people worldwide, but some common therapies bear a shocking resemblance to Speed. A new drug from NLS, Mazindol, just entered Phase II and could set a new non-amphetaminic standard. The treatment of Attention Deficit Hyperactive Disorder (ADHD) is hotly debated in the US, were almost 10% […]

August 30, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 30 Aug 2016

Mice made Transparent to reveal Brain and Blood Networks

uDISCO could be the name of Munich’s newest, hottest club. Indeed, it stands for ‘ultimate DISCO’ and boasts mesmerizing green lights. But it’s actually something much more exciting: it’s a new method that renders mice transparent to improve anatomical imaging. A team of researchers headed by Prof. Ali Ertürk at Ludwig Maximilian University in Munich, […]

August 30, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 30 Aug 2016

Top 10 Best-selling Biologicals of 2015

Biological drugs have revolutionised disease treatment and their developers have made a killing along the way. We take a look at the top selling biologicals of 2015 – and if they are on their way in or out. Since the beginning of modern biotechnology, with Genentech’s recombinant DNA breakthrough, biologicals have created alternative and more specific treatments for […]

August 30, 2016 - 6 minutesmins - By Denise Neves Gameiro

News and Trends 29 Aug 2016

Sanofi’s Phase III Results could make Praluent the next Blockbuster Cholesterol Drug

If you’re only just recovering from Pfizer’s inescapable ad campaign for Lipitor, brace yourself: Sanofi and Regeneron are poised to introduce its successor, Praluent (alirocumab), following its excellent Phase III results. Heart disease is the leading cause of death in Americans over the age of 35, and it contributes significantly to the global mortality rate. […]

August 29, 2016 - 2 minutesmins - By Evelyn Warner

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

This €18M Joint Venture could Scale Up Bioplastic Film Production

Infographic: How Cancer Starts & How It Chooses Organs

Cevec: “Our Special Cell Lines will help the next generation of Gene Therapy”

GSK is Advancing a Revolutionary Dual HIV Therapy

Novartis’ second FDA Biosimilar Approval could unlock Billions

World’s most advanced Artificial Heart started its last Study before Approval

Discover the best Refresh Program we’ve ever made!

No Tumour, No Cancer Cure: New Epigenetic Test can pinpoint Elusive Ones

New non-amphetaminic ADHD drug ‘speeds’ into Phase II

Mice made Transparent to reveal Brain and Blood Networks

Top 10 Best-selling Biologicals of 2015

Sanofi’s Phase III Results could make Praluent the next Blockbuster Cholesterol Drug

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!